GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aethlon Medical Inc (NAS:AEMD) » Definitions » Operating Income

Aethlon Medical (Aethlon Medical) Operating Income : $-12.63 Mil (TTM As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Aethlon Medical Operating Income?

Aethlon Medical's Operating Income for the three months ended in Dec. 2023 was $-3.57 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.63 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Aethlon Medical's Operating Income for the three months ended in Dec. 2023 was $-3.57 Mil. Aethlon Medical's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Aethlon Medical's Operating Margin % for the quarter that ended in Dec. 2023 was %.

Good Sign:

Aethlon Medical Inc operating margin is expanding. Margin expansion is usually a good sign.

Aethlon Medical's 5-Year average Growth Rate for Operating Margin % was 2.90% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aethlon Medical's annualized ROC % for the quarter that ended in Dec. 2023 was -560.19%. Aethlon Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -666.11%.


Aethlon Medical Operating Income Historical Data

The historical data trend for Aethlon Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aethlon Medical Operating Income Chart

Aethlon Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.00 -5.93 -7.89 -10.42 -11.90

Aethlon Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.85 -2.48 -3.41 -3.18 -3.57

Aethlon Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aethlon Medical  (NAS:AEMD) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aethlon Medical's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-14.268 * ( 1 - 0% )/( (2.621 + 2.473)/ 2 )
=-14.268/2.547
=-560.19 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Aethlon Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.268/( ( (2.219 + max(-1.12, 0)) + (2.065 + max(-1.539, 0)) )/ 2 )
=-14.268/( ( 2.219 + 2.065 )/ 2 )
=-14.268/2.142
=-666.11 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.311) - (1.431 + 0 + 0)
=-1.12

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.277) - (1.816 + 0 + 0)
=-1.539

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Aethlon Medical's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.567/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Aethlon Medical Operating Income Related Terms

Thank you for viewing the detailed overview of Aethlon Medical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Aethlon Medical (Aethlon Medical) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Executives
Nicolas Gikakis director 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO CA 92121
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Steven P Larosa officer: Chief Medical Officer 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA 92123
Chetan Shah director 9 GRACE HILL COURT, TITUSVILLE NJ 08560
Fisher Charles J Jr director C/O AETHLON MEDICAL, INC., 9635 GRANITE RIDGE DR., SUITE 100, SAN DIEGO CA 92123
Guy F. Cipriani director 1727 EAGLERIDGE DRIVE, BELLINGHAM WA 98226
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Rodell Timothy C Jr officer: Interim CEO 201 MIDLAND AVE, ASPEN CO 81611
Weiner Family Revocable Trust Ellen R. 10 percent owner 10645 N. TATUM BOULEVARD, SUITE 200-166, PHOENIX AZ 85028
Phillip A Ward director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Thomas V Wornham director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Rodney S Kenley director, officer: President 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
James B Frakes officer: Chief Financial Officer 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
Barry Franklyn S Jr director 1141 DELAWARE AVENUE #3N, BUFFALO NY 14209